developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagsliver disease

#liver disease

All articles tagged with "liver disease"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

GLP-1 shows promise for patients with advanced fatty liver disease

Semaglutide shows antifibrotic signal in advanced MASH trial

Large Phase 2 trial data suggest semaglutide may reduce fibrosis in advanced MASH.
The benefit was reported without worsening liver inflammation.
Patients with compensated cirrhosis were included, addressing a major unmet-need group.
The semaglutide-zalfermin combination did not beat placebo.

DE

DT Editorial Team·Jul 17, 2026·via medicalxpress.com

More in Health→

Stepped alcohol treatment via telehealth reduces alcohol use

Telehealth alcohol care cuts drinking in liver disease study

A randomized trial tested stepped alcohol treatment delivered through telehealth in adults with chronic liver disease.
The intervention did not beat usual care on the primary endpoint but did reduce drinks per week at three and six months.
Thirty-day abstinence at six months was higher in the telehealth group than in usual care.
The results highlight a possible way to bring guideline-recommended alcohol care into liver clinics.

DE

DT Editorial Team·Jul 1, 2026·via medicalxpress.com

More in Health→

Gene therapy shows promise in ARC syndrome, a deadly childhood liver disease

Gene Therapy Clears Early Hurdle in Deadly Childhood Liver Disease

Researchers treated ARC syndrome in mice by delivering a healthy version of the gene linked to the disease.
The final liver-targeted version avoided harms seen in earlier versions that triggered abnormal gene activation and cancerous growth.
The team says more long-term safety work is needed before any human trial can begin.

DE

DT Editorial Team·Jun 19, 2026·via medicalxpress.com

More in Health→

Phase 3 trial links survodutide to liver fat and weight reductions in at-risk MASLD

Phase 3 SYNCHRONIZE-MASLD enrolled 216 adults with obesity and at-risk MASLD.
Both co-primary endpoints were met at week 48: liver fat reduction and weight loss.
Gastrointestinal side effects were most common and generally mild to moderate.

DE

DT Editorial Team·Jun 8, 2026·via nature.com

More in Health→

One in five patients achieve functional hepatitis B cure after 24 weeks of bepirovirsen

Bepirovirsen posts phase III gains in hepatitis B cure push

Two duplicate phase III trials reported functional cure rates of 20% and 19%.
No patients in the placebo groups achieved a functional cure.
About 24% of treated patients were able to discontinue nucleoside analog therapy.

DE

DT Editorial Team·May 29, 2026·via medicalxpress.com

More in Health→

Macrophage cell therapy boosts four-year transplant-free survival in advanced cirrhosis

Macrophage Cell Therapy Shows Long-Term Promise in Advanced Cirrhosis

A MATCH clinical trial compared macrophage cell therapy with standard care in advanced cirrhosis.
After four years, 70% of treated patients were alive without transplant versus 40% in the control group.
Researchers reported no serious side effects in treated patients.

DE

DT Editorial Team·May 25, 2026·via medicalxpress.com

More in Health→

Intercept

Intercept’s INT-787 Setback Adds Pressure in Liver Disease Drug Development

Intercept’s INT-787 failed a Phase 2 study and showed no clear evidence of benefit.
The result appears to end the program’s path forward, according to the supplied report.
The setback increases pressure on Intercept in a difficult liver disease development landscape.

DE

DT Editorial Team·May 7, 2026·via endpoints.news

More in Health→

'Zombie' cells spark inflammation in severe fatty liver disease, Mayo Clinic researchers find - Mayo Clinic News Network (via newsnetwork.mayoclinic.org)

Researchers report a newly identified liver cell that may help explain common liver disease

University of Michigan researchers reported a newly identified liver cell type.
The source says the cell may protect against a common liver disease.
The finding is early but could shape future treatment research.

DE

DT Editorial Team·May 4, 2026·via medicalxpress.com

More in Health→

Rare T Cells Implicated in Inflammatory Cascade Behind Liver Fibrosis

A Julius Maximilian University of Wurzburg study examined immune cell networks in liver disease.
The study links a rare T cell type to signaling that amplifies inflammation.
The inflammatory cascade is reported to contribute to liver fibrosis.
The supplied source text supports a mechanistic finding, not a new treatment.

DE

DT Editorial Team·Apr 21, 2026·via medicalxpress.com

More in Health→

A person wearing all white holds a plastic tube with a pink cap half full of reddish liquid in their two hands covered in purple nitrile gloves.

Blood test under development could detect liver scarring before cancer emerges

The test looks for free-floating DNA in blood associated with liver scarring.
Researchers are using a machine learning model to interpret the biological signal.
The goal is to identify a precursor state that can increase future liver cancer risk.
The assay remains in development and still requires broader validation before clinical use.

DE

DT Editorial Team·Apr 21, 2026·via livescience.com

More in Science→